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The coordination of nutrient and energy availability
with cell growth and division is essential for proper
immune cell development and function. By using a
chemical mutagenesis strategy in mice, we identified
a pedigree that has a complete block in B cell devel-
opment at the pre-B cell stage resulting from a dele-
tion in the Fnip1 gene. Enforced expression of an
immunoglobulin transgene failed to rescue B cell
development. Whereas essential pre-B cell signaling
molecules were activated normally in Fnip1-null pre-
B cells, the metabolic regulators AMPK and mTOR
were dysregulated, resulting in excessive cell growth
and enhanced sensitivity to apoptosis in response to
metabolic stress (pre-B cell receptor crosslinking,
oncogene activation). These results indicate that Fol-
liculin-interacting protein 1 (Fnip1) is vital for B cell
development and metabolic homeostasis and reveal
a metabolic checkpoint that may ensure that pre-B
cells have sufficient metabolic capacity to support
division, while limiting lymphomagenesis caused by
deregulated growth.
INTRODUCTION
The development of all metazoan organisms involves the strict
coordination of cell growth, apoptosis, division, and differentia-
tion. During B lymphocyte development, these processes are
carefully linked to an orchestrated series of ‘‘checkpoints’’ that
ensure that mature B cells can mount an immunogenic response
against foreign antigens, without reacting against self. The
earliest committed B cell progenitor (pro-B cell) is defined by
having its immunoglobulin (Ig) genes in germline (unrearranged)
configuration. The Ig heavy (IgH) chain gene segments rearrange
first, and after successful in-frame VH-to-DHJH juxtaposition, the
IgH chain ‘‘m’’ pairs with surrogate light chain chaperones l5 and
Vpre-B and signal transducing Iga and Igb chains, as a compo-
nent of the pre-B cell receptor (pre-BCR) complex on the surfaceof pre-B cells. The pre-BCR complex then signals pre-B cells to
stop VH-to-DHJH rearrangement of the other IgH allele (a process
called ‘‘allelic exclusion’’), proliferate (synergistically with IL-7
receptor stimulation), start IgL chain (k and l) gene transcription
and rearrangement (VL-JL), and mature. After in-frame IgL chain
rearrangement, the IgH and IgL chains pair to form IgM on the
surface of immature B cells, at which point B cells with low
self-reactivity exit the BM and migrate to peripheral lymphoid
tissues, where development continues (see Goodnow et al.,
2005, for review).
The importance of particular signaling proteins in pre-B cell
development has been demonstrated through a series of
biochemical and gene-targeting studies in mice (see Hendriks
and Middendorp, 2004; Herzog et al., 2009, for review). For
example, formation of the pre-BCR results in activation of the
Src family protein tyrosine kinases (Ptks) Fyn, Lyn, and Blk,
which phosphorylate membrane-bound Iga and Igb on their
immunoreceptor tyrosine-based activation motifs (ITAMs).
This results in the recruitment and activation of the Syk Ptk,
which activates the Ras-Raf signaling pathway and phosphor-
ylates the adaptor protein SLP-65 (also known as BLNK). Phos-
phorylated SLP-65 then forms a signaling module that recruits
and activates multiple pathways including phosphatidylinositol
3-kinase (PI3K) and the Tec family Ptks Btk and Tec, which
activate PLCg1/2 and ultimately Ca2+ flux. These events alto-
gether lead to activation of essential transcriptional mediators
including Erk, Myc (Habib et al., 2007), IRF-4/8, Foxo1, and
NF-kB (see Herzog et al., 2009; Kurosaki et al., 2010, for
review).
In this study, we utilized a phenotype-driven ‘‘reverse-
genetic,’’ recessive ethylnitrosourea (ENU)mutagenesis strategy
in mice to discover genes involved in immune cell development
and function (see Appleby and Ramsdell, 2003; Cook et al.,
2006, for review). In the course of this program, we identified a
pedigree (denoted LPAB.1) that selectively lacks B cells in
peripheral blood. By genome scanning, the B cell immunodefi-
ciency phenotype was mapped to a noncoding deletion in the
Fnip1 gene, which encodes for the 160 kDa protein Folliculin
interacting protein-1 (Fnip1) (Baba et al., 2006). Although the
biological functions of Fnip1 and the related Fnip family member
Fnip2 (Hasumi et al., 2008; Takagi et al., 2008) are unknown, both
molecules interact with Folliculin and AMP kinase (Baba et al.,Immunity 36, 769–781, May 25, 2012 ª2012 Elsevier Inc. 769
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Figure 1. LPAB.1 Mice Lack Peripheral B Cells and Have a Deletion in the Fnip1 Gene
(A) Flow cytometric analyses of peripheral blood samples from LPAB.1 and WT mice revealed the absence of B220+ B cells, whereas CD3ε+ T cells were
represented normally.
(B) A PCRgenotyping strategy was designedwith oligonucleotides spanning the 32 bp deleted region in the Fnip1 gene. Shown is an ethidium-stained acrylamide
gel containing PCR products amplified from WT, Fnip1+/, and Fnip1/ genomic DNA.
(C) Representative immunoblot showing the absence of Fnip1 protein in testis, bone marrow cells (BM), and blood from Fnip1/mice relative to WT littermates.
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Fnip1 Is Essential for B Cell Development2006; Hasumi et al., 2008), a highly conservedmaster sensor and
regulator of cellular metabolism (see Towler and Hardie, 2007,
for review). In response to low energy (low ATP, high AMP),
AMPK is activated by phosphorylation at threonine 172 by
LKB1 kinase. Activated AMPK then stimulates ATP production
by increasing glucose uptake, stimulating mitochondrial biogen-
esis, and increasing glycolysis and oxidative phosphorylation (by
inducing expression of the PGC1a and PPAR-g transcription
factors). AMPK also decreases ATP consumption by inhibiting
mammalian target of rapamycin (mTOR)-driven cell growth, in
part by phosphorylating and activating the mTOR inhibitor
tuberous sclerosis protein 2 (TSC2) (Inoki et al., 2003) and by
phosphorylating and inactivating the mTOR-positive regulatory
protein Raptor (Gwinn et al., 2008). Our studies indicate that
Fnip1 maintains metabolic homeostasis in developing B cells
and reveal a metabolic ‘‘checkpoint’’ during B cell development,
which we hypothesize may ensure that mature B cells are
adequately equipped to fuel clonal expansion and antibody
production, while protecting the host against excessive growth
and transformation.
RESULTS
Generation of Fnip1-Null Mice by ENU Mutagenesis
We screened G3 mice from a large-scale ENU mutagenesis
project for recessive mutations leading to specific immunodefi-
ciencies. By utilizing flow cytometry to assess the representation
of immune cells in peripheral blood, we identified the LPAB.1
pedigree based on an absence of B lymphocytes (Figure 1A),
whereas myeloid and T cells were represented normally. By
mapping affected G3 animals via positional cloning strategies,
the LPAB.1 mutation was localized to a 1.7 Mb interval on chro-770 Immunity 36, 769–781, May 25, 2012 ª2012 Elsevier Inc.mosome 11. We sequenced candidate genes and identified a
32 bp deletion in exon 9 of a putative gene (A730024A03Rik),
which resulted in the generation of a premature stop codon at
residue 293 (Figure S1A available online). The product of
A730024A03Rik was subsequently identified as the murine
homolog of Fnip1 (Baba et al., 2006). PCR analysis confirmed
that the deletion (Figure 1B) tracked with the B cell immunodefi-
ciency and immunoblotting with a-Fnip1 revealed the absence of
Fnip1 protein in tissues from LPAB.1 (Fnip1/) mice (Figure 1C).
Fnip1/mice were viable and fertile but exhibited several addi-
tional phenotypes relative to wild-type (WT) littermates, including
alterations in skeletal muscle (which appeared deep red as a
result of high mitochondria content), increased liver glycogen
content, and hypertrophic cardiomyopathy (data not shown).
Taken together, these results indicate that the lack of B cells in
LPAB.1 mice maps to a deletion in the Fnip1 gene, which results
in the absence of Fnip1 protein.
Fnip1 Is Expressed in Multiple Tissues
We examined the expression of Fnip1 in 25 different normal
mouse tissues (Park et al., 2008) by real-time PCR. We found
that Fnip1 was highly expressed in testes, kidney, skeletal
muscle, liver, heart, and embryo, in addition to thymus, spleen,
and bone marrow (BM) (Figure S1B). Fnip1 was equally
expressed in FACs-sorted B lineage cells throughout B cell
development, whereas Fnip2 expression sharply increased
during B cell development, reaching maximal levels in immature
B cells (Figure S1C). Although both Fnip1 and Fnip2 were
expressed in thymocytes, neither showed regulated expression
during T cell development (Figure S1D). Transfection of Flag-
tagged Fnip1 into the WEHI B cell line indicated that Fnip1
protein resides in the cytoplasm (Figure S1E), as was previously
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collectively suggest that Fnip1 is normally expressed in multiple
tissues including hematopoietic cells and encodes for a cyto-
plasmic protein in B cells.
Absence of Fnip1 Blocks B Cell Development
at the Large, Pre-B Cell Stage
To examine where loss of Fnip1 blocks B cell development, total
BM cells and splenocytes were stained with antibodies against
proteins that are differentially expressed during B cell develop-
ment (Figure 7D). Analysis of Fnip1/ BM revealed a complete
block at the B220+CD43+CD25MHCII large pre-B cell stage
(Figure 2A), which resulted in the absence of mature B cells
bearing IgM, CD21, and CD23 in the BM and spleen (Figures
2A and 2B). Fnip1/ mice also lacked ‘‘B1’’ B lymphocytes,
which represent a subset of B cells that are found in the perito-
neal and pleural cavities (Figure 2C; Hardy and Hayakawa,
2001). Fnip1/ mice failed to produce serum Igs of all isotypes
after immunization with keyhole limpet hemocyanin (KLH) (Fig-
ure 2D). Intracellular (IC) flow cytometric analyses indicate
that Fnip1/ BM B cells contain IC IgH ‘‘m’’ protein but lack IC
IgL ‘‘k’’ (Figure 2E). These results suggest that loss of Fnip1
results in a complete block in B cell development at the large
pre-B-to-small pre-B cell transition mediated by formation of
the pre-BCR (Figure 7D; Hardy and Hayakawa, 2001).
We next examined the ability of Fnip1/ pre-B cells to divide
and survive in the presence or absence of the growth factor IL-7.
CFSE analyses indicated that Fnip1/ pre-B cells divide equally
well as WT pre-B cells in vitro in response to IL-7 (Figure S2A),
whereas the proliferation of Rag2/ pro-B cells is blunted as
a result of the absence of pre-BCR formation, which normally
synergizes with IL-7 for maximal proliferation (Fleming and
Paige, 2002). Fnip1/ pre-B cells also divided equally well as
WT pre-B cells in vivo, based on equivalent incorporation of
BrdU after 48 hr (Figure S2B). Fnip1/ B220+CD43mid pre-B
cells, but not B220+CD43hi pro-B cells, exhibited significantly
decreased viability relative to WT pre-B cells (Figure 2F). Anti-
body-mediated crosslinking of Igb, which mimics pre-BCR
crosslinking, induced apoptosis of Fnip1/ pre-B cells and
failed to stimulate pre-B cell development, whereas Rag2/
pro-B cells were induced to mature based on downregulation
of CD43 (Figure 2G) and upregulation of CD25 (Kouro et al.,
2001). Relative to WT pre-B cells, Fnip1/ pre-B cells ex-
pressed normal mRNA levels of the antiapoptotic molecule
Bcl2 and slightly decreased levels of the proapoptotic molecule
Bim (Figure S2C) and were equally sensitive to apoptosis in
response to the protein kinase inhibitor staurosporine (Fig-
ure S2D) or Fas crosslinking (Figures S2E), suggesting that
apoptosis is relatively specific to activation. These results
suggest that Fnip1/ pre-B cells fail to mature in response to
pre-BCR signals, whereas proliferative signals emanating from
the pre-BCR and the IL-7 receptor are transmitted relatively
normally.
Enforced Expression of IgH, IgL, or IgM Fails to Rescue
B Cell Development in Fnip1-Null Mice
Wenext testedwhether the experimental provision of rearranged
IgH and/or IgL chains in Fnip1/ mice could overcome the
arrest in B cell development. Fnip1/ and Rag2/ (control)mice were crossed with IgMHEL mice, which carry a rearranged
IgH chain ‘‘knockin’’ allele (denoted IgHHEL) and a separate
IgL ‘‘k‘‘ transgene (denoted IgLHEL), which together encode
surface IgM specific against hen egg lysozyme (HEL) protein
(Allen et al., 2007). We assessed whether IgHHEL, IgLHEL, or
IgHHEL plus IgLHEL (IgMHEL) could stimulate B cell development
in Fnip1/ and Rag2/ control mice. Expression of a rear-
ranged IgH chain (IgHHEL), which mimics pre-BCR expression,
efficiently drove B cell maturation in Rag2/ mice based on
downregulation of CD43 upregulation of CD25 and MHC II
(Figure S3A), and a reduction in cell size (data not shown). In
contrast, IgHHEL was unable to stimulate B cell maturation in
Fnip1/ mice, suggesting that pre-BCR signaling is impaired.
Similarly, expression of a rearranged IgL chain (IgLHEL Tg), which
pairs with endogenous Fnip1/ IgH chains to form surface IgM,
also failed to stimulate Fnip1/ pre-B cell progenitors to mature
(Figures S3B–S3D). Remarkably, live-gated Fnip1/ B cell
progenitors that expressed both IgHHEL and IgLHEL (IgMHEL) still
failed to mature (Figure 3A) and migrate to the periphery (Fig-
ure 3B) despite high-level IgM expression, which potently drove
B cell development and migration to the periphery in Rag2/
mice. Fnip1/ IgMHEL BM B cells exhibited a ‘‘tolerant-like’’
phenotype consisting of CD62L, B220lo, and IgMlo and were
more sensitive to apoptosis in response to anti-IgM (data not
shown). These results demonstrate that Fnip1 is absolutely
required for pre-BCR-mediated B cell differentiation and
suggest a potential role for Fnip1 in BCR-mediated maturation
and survival.
Allelic Exclusion of the Ig Heavy Chain Occurs Normally
in the Absence of Fnip1
It has previously been shown that expression of a rearranged IgH
chain in pro-B cells mimics pre-BCR formation, resulting in
suppression of endogenous IgH chain gene rearrangement
(allelic exclusion) (Nussenzweig et al., 1987). Therefore, we
utilized IgMHEL mice to ask whether expression of IgHHEL and
IgLHEL, which together form IgM of the ‘‘a’’ isotype (IgMa), would
extinguish expression of endogenous m chains (IgMb) in Fnip1/
B cells. As shown in Figure 3C, WT C57BL6 mice express
surface IgMb, whereas Fnip1/ mice lack IgM expression
because of the absence of IgL chains. Expression of IgLHEL Tg
in Fnip1/mice restored surface expression of IgMb. However,
when Fnip1/ mice were bred to IgHHEL/+IgLHEL/+ mice (IgMa),
all B cells expressed IgMa and not endogenous IgMb, indicating
that signals delivered from the IgMHEL efficiently extinguished
rearrangement and expression of the endogenous Igm in
Fnip1/ mice.
Impaired B Cell Development in Fnip1-Null Mice Is Cell
Autonomous
To determine whether the defects in B cell development are
autonomous to Fnip1/ pre-B cells, we transferred total BM
cells from WT (CD45.1+), Fnip1/ (CD45.2+), or mixed WT and
Fnip1/ cells into lethally irradiated Rag2/Il2rg/ (recombi-
nase activating gene 2/common g chain double null) hosts
(CD45.2+) (Garcia et al., 1999). The development of donor hema-
topoietic cells were analyzed 15 weeks after transplantation.
As shown in Figure S6, Rag2/Il2rg/ completely lacked all
lymphocytes as a result of complete blocks in B and T cellImmunity 36, 769–781, May 25, 2012 ª2012 Elsevier Inc. 771
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Figure 2. Loss of Fnip1 Results in a Complete Block in B Cell Development at the Pre-B Cell Stage
(A–C) BMcells (A), splenocytes (B), and peritoneal cells (C) derived from Fnip1/ andWTmicewere stainedwith fluorescent-conjugated antibodies and analyzed
by flow cytometry. Shown are representative histograms (of eight mice/group). B1a, B1b, and B2 refer to types of B cells (Hardy and Hayakawa, 2001).
(D) Fnip1/ andWTmice (fivemice per group) were immunized with KLH, and sera were tested for KLH-specific antibodies by ELISA. Bars represent the mean ±
standard error of the mean (SEM).
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Fnip1 Is Essential for B Cell Developmentdevelopment at the pro-B and the CD4CD8 cell stages,
respectively. Transfer of WT BM cells rescued the development
of B220+IgM+ B, GR1+ myeloid, and CD4+ and CD8+ T cells. In
contrast, transfer of Fnip1/ BM rescued the development of
CD4+ and CD8+ T cells but failed to restore the development of
Fnip1/ B cells. Transfer of a 1:1 mixture of CD45.1+
WT:CD45.2+ Fnip1/ BM cells rescued the development of
both WT and Fnip1/ T cells and GR1+ myeloid cells, but only
WT CD45.1+ (CD45.2) IgM+ B cells. These results indicate
that the defect in the development of Fnip1/ B cells is cell
autonomous and is not due to a defective BM environment or
secretion of a B cell inhibitory factor.
Retroviral Expression of Fnip1 Rescues B Cell
Development in LPAB.1 Mice
To confirm that the absence of Fnip1 is directly responsible for
the LPAB.1 phenotype, we infected lineage-negative (Lin) BM
cells from Fnip1/ mice with empty MSCV retrovirus or with
MSCV containing full-length Fnip1 cDNA and transplanted the
cells into Rag2/Il2rg/mice. Empty MSCV-infected Fnip1/
BM cells failed to restore B cell development after transplant
into Rag2/Il2rg/ hosts, while CD4+ and CD8+ T cells are
efficiently rescued to normal levels, confirming successful
engraftment of Fnip1/ donor HSCs (Figure S7A). In contrast,
transfer of MSCV-Fnip1-infected Fnip1/ BM also rescued
the development of conventional B220+IgM+ B cells and CD5+
IgM+ ‘‘B1’’ B cells. These results demonstrate that loss of
Fnip1 is directly responsible for the B cell immunodeficiency
phenotype in LPAB.1 mice.
Fnip1-Null Pre-B Cells Exhibit Changes in Gene
Expression Indicative of Altered Cellular Metabolism
To examine why loss of Fnip1 might result in impaired pre-B cell
development, we FACS sorted B220+CD43+ cells from Fnip1/
and WT littermate mice and examined the global differences in
gene expression via cDNA microarray technology. We found
293 genes significantly increased and 246 genes decreased in
Fnip1/ pre-B cells relative toWTpre-B cells, based on p values
<0.05 (Figure S4). Kyoto Encyclopedia of Genes and Genomes
(KEGG) analyses revealed a large percentage of the changes
involved genes controlling cell metabolism and mitochondrial
biogenesis and function. In particular, we found substantial
increases in the expression of AMPK-regulated ‘‘catabolic’’
genes including the transcriptional coactivators peroxisome
proliferator-activated receptor gamma coactivator-1a and
b (Ppargc1a [Pgc1a] and Ppargc1b [Pgc1b]), which are ‘‘master’’
regulators of fatty acid oxidation (FAO) and mitochondrial
biogenesis (Figure S4). This correlated with a significant increase
in the expression of genes involved in fatty acid metabolism and
mitochondrial function. Surprisingly, we also found increases in(E) BM cells from Fnip1/, Rag2/, and WT mice were intracellularly stained w
staining. Shown are representative flow cytometric histograms obtained from fiv
(F) Decreased cell viability of B220loCD43mid BM cells from Fnip1/mice. BM ce
by flow cytometry. Bar graphs depict percent apoptotic-dead (7AAD+) cells (mea
from three mice per group.
(G) Rag2/ and Fnip1/ mice were injected intraperitoneally with 250 mg of a-
antibodies specific to B220, CD43, and Annexin V. Anti-Igb stimulates the devel
See also Figure S2.‘‘anabolic’’ genes involved in cellular growth such as ribosomal
S6 kinase-1 (Rps6kb1), ribosome protein L3 (Rpl3), and Ras-
related GTP binding proteins B (Rragb) and D (Rragd), which
are positive regulators of mTOR activation and/or function
(Figure S4).
We next determined whether these global changes in gene
expression were reflective of the biology of Fnip1/ pre-B cells.
First, by utilizing real-time PCR, we confirmed significantly
increased expression of essential AMPK-regulated catabolic
genes including Pgc1a (Pparg coactivator 1a), Pparg (peroxi-
some proliferator-activated receptor g) (Narkar et al., 2008),
and 4f2hc (solute carrier family 3, member 2) (Towler and Hardie,
2007), and the glucose transporter Glut1 (Rathmell et al., 2000),
which is the main glucose transporter in lymphocytes, in
Fnip1/ versusWT pre-B cells (Figure 4A). In addition, essential
mitochondrial genes including Ucp3 (uncoupling protein 3),
Atp5g1 (mitochondrial ATPase, C1 subunit), andmt-Cytb (Cyto-
chrome b) were also significantly increased in pre-B cells from
Fnip1/ mice relative to WT mice (Figure 4A). Flow cytometry
and transmission electron microscopy (EM) analyses further
revealed that Fnip1/ B cell progenitors exhibited increased
labeling with the mitochondrial dye MitoTracker green relative
to WT B cell progenitors (Figure 4B) and contained significantly
increased numbers of mitochondria (Figure 4C). Fnip1/ B cell
progenitors took up the fluorescent deoxyglucose analog
2-NBDG more effectively than did WT pre-B cells in response
to IL-7 (Figure 4D). These results confirmed that the upregulated
AMPK and PGC-1a gene signature correlates with increased
AMPK and PGC1a function in Fnip1-null pre-B cells. To deter-
mine whether the upregulated mTOR gene signature correlated
with increased cell growth, we examined mTOR activation and
cell size by flow cytometry. We found that relative to WT pre-B
cells, Fnip1/ pre-B cells exhibited increased intracellular phos-
pho-S6 ribosomal protein (pS6R) (Figure 4E), which is a down-
stream mediator of mTOR signaling that stimulates ribosome
biogenesis and translation and are significantly larger in size
relative to WT pre-B cells and Rag2/ pro-B cells (Figure 4F).
These results collectively suggest that loss of Fnip1 results in
parallel increases in catabolic metabolism and mTOR-mediated
anabolic metabolism, two normally antagonistic energy-
regulating processes that typically occur separately.
Fnip1 Controls the Ability of AMPK to Inhibit
mTOR-Mediated Cell Growth
Although the cellular and molecular functions of Fnip1 are
unknown, both Fnip1 (Baba et al., 2006) and Fnip2 (Hasumi
et al., 2008; Takagi et al., 2008) have been shown to interact
with all three subunits (a, b, g) of AMPK. To examine how
Fnip1 might interact with pre-BCR signaling and metabolism,
we assessed the presence and activation of known pre-BCRith fluorescent-conjugated a-Igm (top) and a-Igk (bottom) after a-B220 surface
e mice per group.
lls were stained with a-B220, a-CD43, and 7AAD. Cell viability was determined
n ± SEM) on gated B220+CD43hi cells or B220+CD43mid cells. p value is shown
Igb mAb HM79. On day 7 postinjection, bone marrow cells were stained with
opment of Rag2/ pro-B cells but induces apoptosis of Fnip1/ pro-B cells.
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Figure 3. Enforced Expression of Ig Heavy and Ig Light Chains Fail to Drive B Cell Development in Fnip1-Null Mice, whereas Allelic Exclusion
Occurs Normally
(A and B) Total BM cells (A) and splenocytes (B) from WT, Rag2/, Rag2/IgHHELIgLHEL, Fnip1/, and Fnip1/IgHHELIgLHEL mice were analyzed by flow
cytometry utilizing the indicated fluorescent-conjugated antibodies. IgMHEL stimulates the development of Rag2/ pro-B cells but fails to stimulate the
maturation of Fnip1/ pre-B cells. Representative histograms of five mice per group are shown.
(C) Allelic exclusion occurs normally in Fnip1/mice. Total BM cells from the indicated mice were stained with fluorescent-conjugated a-B220 and HEL (top) or
a-IgMa and a-IgMb (bottom). Shown are representative flow cytometric histograms from four mice per group.
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Figure 4. Loss of Fnip1 Results in Metabolic Dysregulation in Pre-B Cells Defined by Increased Expression of AMPK and mTOR-Regulated
Genes, Increased Mitochondrial Biogenesis, and Increased mTOR-Mediated Cell Growth
(A) Purified pre-B cell cDNA from Fnip1/ and WT mice were subjected to real-time PCR specific for the indicated genes. Bars indicate means ± SEM of three
mice per group. p values are shown.
(B) Increased mitochondria in Fnip1/ pre-B cells. Fnip1/ andWT BM cells were stained with a-B220, a-CD43 plus the mitochondrial dye MitoTracker green.
Shown is a representative flow cytometric histogram (n = 3 mice per group) of gated B220+CD43+ cells.
(C) Transmission electron micrographs were obtained on FACS-sorted pre-B cells from three WT and three Fnip1/ mice. Left: Representative high-power
images (20,0003). Right: The number of mitochondria per field were enumerated in the cytoplasmic compartment for 8 WT and 17 Fnip1/ pre-B cells. Bars
indicate means ± SEM; p < 0.00006.
(D) Increased glucose uptake in Fnip1/ pre-B cells. Total BM cells were cultured inmedia, IL-7, IL-3, or insulin at the indicated concentrations for 48 hr. 2-NDBG
was added for the last 3 hr. Shown is bar graph (n = 3 per group for IL-7, n = 2 per group in triplicate for IL-3, insulin) showing the relative fluorescence intensity of
B220+IgM gated cells as assessed by flow cytometry. Error bars indicate mean ± SEM. p values are shown.
(E) Fnip1/ and WT BM cells were stained with a-B220, a-CD43, and intracellular pS6R. Shown is a representative histogram.
(F) Shown is a representative forward-light scatter (FSC) histogram overlay comparing the size of gated B220+IgM pro-B and pre-B cells fromWT, Rag2/, and
Fnip1/ mice.
See also Figure S4.
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Figure 5. Dysregulated mTOR Signaling in Fnip1–/– Pre-B Cells
(A) B cell progenitors from Rag2/ and Fnip1/ mice were activated with
a-Igb at the indicated time points. Immunoblots were probed with antibodies
against total phosphotyrosine.
(B) Fnip1/ andWTmice were injected with the AMPK-activator AICAR. Total
BM cells from untreated or AICAR-treated mice were isolated 18 hr post-
injection and B220+CD43+ cells were FACS sorted. Immunoblots (represen-
tative of 3–4 experiments) were performed with the indicated antibodies.
a-tubulin was utilized as a loading control.
See also Figure S5.
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(Nagata et al., 1997). Crosslinking of Igb on purified B cell
progenitors from Fnip1/ and Rag2/ control mice resulted
in equivalent increases in total tyrosine (Figure 5A) or serine/
threonine phosphorylated proteins including Syk, Blnk (Slp65),
Btk, Akt, Erk, and IKKa/b (Figure S5A), suggesting that pre-
BCR signaling is activated normally in the absence of Fnip1.
Fnip1/ mice also expressed normal levels of Cd79a (Igb),
Tcf3 (E2a), Irf4 and Irf8, Pax5, and other important pre-BCR
signaling molecules relative to WT mice (Figure S5B). Activation
of Fnip1/ B cell progenitors with the AMPK activator 5-amino-
imidazole-4-carboxyamide-1-beta-D-ribofuranoside (AICAR)
resulted in equivalent activation of AMPK, based on phosphory-
lation levels of AMPK (Thr172) and the AMPK-target acetyl-CoA
carboxylase (ACC) (Figure 5B). However, whereas activation of776 Immunity 36, 769–781, May 25, 2012 ª2012 Elsevier Inc.AMPK with AICAR inhibited S6 kinase-induced phosphorylation
of S6 ribosomal protein (S6R) in WT pre-B cells (indicative of
decreased mTOR function), activation of AMPK failed to inhibit
phosphorylation of S6R in Fnip1/ pre-B cells (Figure 5B),
which paralleled our findings with flow cytometry (Figure 4E).
AMPK appeared to phosphorylate (and presumably inhibit) the
mTOR partner Raptor normally in the absence of Fnip1 (Gwinn
et al., 2008). Akt (a positive regulator of mTOR) was phosphory-
lated normally at the Thr308 and Ser473 activation sites (Sen-
gupta et al., 2010) in the absence of Fnip1 (Figures S5A and
S5C). These results collectively suggest that Fnip1 is not
required for activation of AMPK or AMPK-mediated catabolism
but is important for AMPK to inhibit mTOR.
Loss of Fnip1 Increases Sensitivity to Nutrient
Deprivation-Induced Apoptosis and Developmental
Arrest
Because Fnip1/ pre-B cells exhibited increased mTOR activa-
tion and cell growth (which consumes nutrients), even in the
presence of activated AMPK (low energy), we reasoned that
perhaps Fnip1 loss results in a ‘‘nutrient and energy deficit,’’
which may trigger apoptosis or anergy in Fnip1/ pre-B and
Fnip1/IgMHEL B cells after pre-BCR or BCR crosslinking,
when energy and nutrient demands increase sharply to accom-
modate cell division. First, we tested whether a ‘‘nutrient-rich’’
environment would increase survival of Fnip1/ B cells by
culturing BM cells or sorted pro-B cells from Fnip1/ or WT
mice in nutrient-rich media. Surprisingly, culture of total BM (Fig-
ure 6A) or sorted B220+CD43+ pre-B cells (Figure 6B and data
not shown) in B cell growth media (10% fetal calf serum, 1%
nonessential amino acids, 1% L-glutamine, 1% sodium pyru-
vate, b-mercaptoethanol) rescued a small population of IgM+
Fnip1/ B cell progenitors, which increased by 48 hr but
decreased thereafter because of increased apoptosis. The total
number of IgM+ Fnip1/BMcells emerging in vitro increased up
to 2-fold by adding a cocktail of IL-7/SCF/Flt3 ligand (Figures 6A
and 6B) and was associated with increased intracellular Igk
protein expression (data not shown).
We next determined which nutrients are most critical for the
development of IgM+ Fnip1/ B cells. We found that culturing
pre-B cells in glucose- or glutamine-free media prevented the
emergence of Fnip1/ IgM+ B cells at concentrations where
the emergence of WT IgM+ B cells were relatively unaffected
(Figure 6B and data not shown). Furthermore, removal of essen-
tial amino acids (EAA) significantly inhibited the development of
Fnip1/ IgM+ B cells, which could be rescued in a dose-depen-
dent manner by the addition of EAAs (Figure 6C). Administration
of oligomycin, which blocks ATP synthase and oxidative phos-
phorylation, also inhibited the emergence of Fnip1/ IgM+ B
cells at concentrations that do not affect the development of
WT IgM+ B cells (Figure 6D).
To examine why Fnip1/B cells might be in metabolic deficit,
we analyzed pre-B cell metabolism on FACS-sorted pre-B cells
with the Seahorse Extracellular Flux Analyzer. Fnip1/ pre-B
cells have decreased basal oxygen consumption rate (OCR),
which is a measure of oxidative phosphorylation (OXPHOS) (Fig-
ure 6E). OCR and extracellular acidification rate (ECAR), which is
a measure of glycolysis, could be restored to a hypermetabolic
state in Fnip1/ pre-B cells by the addition of IL-7, which
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Figure 6. Loss of Fnip1 Alters Metabolic Homeostasis and Sensitizes Pre-B Cells to Nutrient and IL-7 Restriction
(A) In vitro nutrient supplementation partially rescues IgM expression in Fnip1/ B cell progenitors. Total BM derived fromWT and Fnip1/mice were grown in
complete B cell growth media for 0, 24, or 48 hr in the presence or absence of growth factors (IL-7, SCF, and Flt-3L). Cells were analyzed by a flow cytometry with
fluorescent-conjugated a-B220 and a-IgM. Bars represent the means ± SEM from six mice per group.
(B) Depletion of glucose or glutamine inhibits the development of Fnip1/ pre-B cells in vitro. FACS-sorted B220loIgM cells were grown in completemedia in the
presence or absence of growth factors, glucose, or glutamine for 48 hr. Cells were analyzed by a flow cytometry with fluorescent-conjugated a-B220 and a-IgM.
Bars represent the means ± SEM from WT (n = 3) and Fnip1/ (n = 6) mice.
(C and D) Total BM were cultured in complete media for 48 hr in the presence of (C) different amounts of essential amino acids (no aa, or 13, 23, or 43 aa) or (D)
oligomycin (0, 1, 5, 10, 50 nM). Cells were analyzed by a flow cytometry with fluorescent conjugated a-B220 and a-IgM. Bars represent themeans ± SEM fromWT
(n = 4) and Fnip1/ (n = 4) mice on gated B220lo populations.
(E and F) Oxygen consumption rate (OCR) and extracellular acidification (ECAR) were measured with a Seahorse Bioscience extracellular flux analyzer over the
course of 150min. FACS-sorted pro-/pre-B cells from Fnip1+/ and Fnip1/BMwere cultured in the absence or presence of growth factors (10 ng/ml of IL-7 and
SCF) for 24 hr prior to analyses.
(E) OCR and ECAR were then measured within 5 min of culture. Shown is the mean ± SEM from five mice per group. p values are shown.
(F) OCR were measured within 5 min of culture in the presence of 2-deoxyglucose (2-DG) or etomoxir (ETMX). Shown is the decrease in OCR after treatment
relative to pretreatment baseline. Mean ± SEM (three mice per group).
(G) ATP levels from FACS-sortedWT (n = 3) and Fnip1/ (n = 3) pre-B cells were determined with a luciferase assay. Mean ± SEM (threemice per group). p values
are shown.
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balance (Figures 6E; Rathmell et al., 2001). Fnip1/ pre-B cells
also exhibited increased sensitivity to 2-deoxyglucose (glycol-
ysis inhibitor) and etoxomir (fatty acid oxidation inhibitor) (Fig-
ure 6F), which correlated with decreased basal ATP levels
relative to WT pre-B cells (Figure 6G).To examine whether increased PPARg or dysregulated mTOR
(Figure S5D) are responsible for impaired B cell development in
Fnip1/ mice, we first cultured BM cells from Fnip1/ mice in
B cell growth media with or without different concentrations of
the specific PPARg-inhibitor GW9662 (Bendixen et al., 2001).
We found that inhibiting PPARg did not rescue nutrient-mediatedImmunity 36, 769–781, May 25, 2012 ª2012 Elsevier Inc. 777
Figure 7. Loss of Fnip1 Inhibits Pre-B Cell Lymphomagenesis Induced by the Em-Myc Transgene
(A) Disruption of the transmembrane portion of Igm (mMT) or Fnip1 (Fnip1/) in mice blocks B cell development at the pre-B cell stage. BM cells from B cell-
deficient Fnip1/ or mMT (control) mice were stained with fluorescent-conjugated antibodies and analyzed by flow cytometry.
(B) Fnip1/ or mMTmice were bred to Em-Myc transgenicmice. Mice were euthanized when lymphomaswere detected. Kaplan-Meier lymphoma-free estimates
are shown forMycFnip1+/+ (n = 33),MycFnip1+/ (n = 66),MycFnip1/ (n = 24), andMycmMT (n = 13). Lymphoma-free curves are significantly different between
MycFnip1+/ andMycFnip1/ (p < 0.0001),MycFnip1+/+ andMycFnip1/ (p < 0.0004),MycmMT andMycFnip1/ (p < 0.0001), andMycmMT andMycFnip1+/
(p < 0.0001) by Log Rank Mantel-Cox Test.
(C) Disruption of Fnip1 results in increased apoptosis of Myc-expressing pre-B cells.MycFnip1/ andMycFnip1+/ BMwere stained with a-B220, a-CD43, and
Annexin V. Shown is a bar graph (mean ± SEM, three mice per group) depicting the percent Annexin V-positive cells within a B220+CD43+ gate.
(D) Amodel of B cell development (modified from Hardy and Hayakawa, 2001), characterized by the differential expression of surface and intracellular molecules.
Shown are the stages whereby loss of Fnip1, Rag2, or Igm (mMT) result in arrested B cell development.
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Fnip1 Is Essential for B Cell DevelopmentIgM expression in Fnip1/ pre-B cells (Figure S7B), suggesting
that increased expression of PPARg (Figure 4A) may reflect an
attempt to maintain energy balance in response to dysregulated
mTOR. Likewise, activation of PPARg in WT pre-B cells with the
agonist troglitazone did not inhibit pre-B to immature B cell
development, although the cells exhibited increased nonspecific
apoptosis (Figure S7C). Injection of Fnip1/ mice with the
mTORC1-inhibitor rapamycin also failed to rescue B cell devel-
opment in vivo. However, delivery of a combination of rapamcyin
and IL-7 (which increases glucose uptake) were sufficient to
rescue the emergence of IgM+ cells in Fnip1/ mice after
2 weeks (Figure S7D). These results collectively suggest that
loss of Fnip1 results in excessive mTOR-mediated metabolite
consumption, increased nutrient demand, impaired OXPHOS,
and IL-7 ‘‘addiction,’’ which prevent the development of pre-B
cells in response to nutrient stress and pre-BCR crosslinking.
Fnip1 Deficiency Inhibits Pre-B Cell Transformation
by c-Myc
Because cancer cells have highmetabolic demands, we hypoth-
esized that disruption of Fnip1 might sensitize pre-B cells to
oncogene-induced apoptosis. To test this hypothesis, we bred
Fnip1/ mice to mice that overexpress the c-Myc oncogene778 Immunity 36, 769–781, May 25, 2012 ª2012 Elsevier Inc.under control of the Ig heavy chain enhancer Em (TgN(IgHMyc)
22Bri [also known as Em-Myc]). Em-Myc transgenic mice typically
develop pre-B cell lymphomas at around 8–30 weeks of age
(Adams et al., 1985). As a control, we also bred Fnip1/ mice
to Ighmtm1Cgn (also known as mMT) mice, which are also arrested
in B cell development at the pre-B cell stage as a result of
targeted disruption of the transmembrane portion of Igm (Fig-
ure 7A; Kitamura and Rajewsky, 1992). Em-MycFnip1/+ or +/+
mice exhibited nearly identical Kaplan-Meier lymphoma-free
curves (Figure 7B), indicating that loss of one allele of Fnip1
has no effect on pre-B cell transformation by c-Myc. Targeted
disruption of Igm resulted in accelerated B cell transformation
by c-Myc (Em-MycmMT), probably because B cell development
is arrested at an IL-7-responsive pre-B cell stage (Herzog
et al., 2009). In contrast, despite a similar block in B cell develop-
ment (Figure 7A) disruption of Fnip1 in Em-MycFnip1/ mice
nearly completely inhibited pre-B cell lymphomagenesis
induced by c-Myc. Inhibition of pre-B cell transformation was
associated with increased apoptosis of B220+CD43+ Em-Myc
Fnip1/ pre-B cells relative to Em-Myc Fnip1/+ pre-B cells (Fig-
ure 7C), whereas cell division was unaffected (data not shown).
These results collectively demonstrate that Fnip1 is important
for the generation of pre-B cell lymphomas induced by c-Myc.
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Resting B lymphocytes respond to foreign pathogens by rapidly
shifting from a quiescent state to a metabolically activated
phenotype, characterized by massive increases in macromolec-
ular synthesis necessary for cell growth, division, and eventually
Ig synthesis (see Rathmell, 2004, for review). The inability to
accommodate these demanding bioenergetic processes would
result in dysfunctional B cells and an immunodeficient host.
Conversely, deregulated cell growth could result in lymphoma-
genesis and the demise of the host. In this study, we utilized
an ENU mutagenesis screen in mice to identify a new B cell
immunodeficient strain, caused by a noncoding deletion in the
Fnip1 gene. Our studies suggest that Fnip1 normally acts as
a molecular switch to permit pre-B cell differentiation and
survival in response to adequate metabolic balance, while
turning off cellular growth. Disruption of Fnip1 results in
metabolic imbalance, which triggers apoptosis in response to
‘‘metabolic stress’’ such as pre-BCR stimulation, nutrient
deprivation, or oncogene activation. We hypothesize that this
‘‘metabolic checkpoint’’ may ensure that maturing B cells have
adequate metabolic capacity to fuel clonal expansion and to
produce Igs while also attenuating deregulated cell growth and
transformation.
Our analysis of Fnip1/Bcell progenitors reveals that Fnip1 is
very unique in how it intersects with known pre-BCR signaling
pathways. First, enforced expression of potent IgMHEL signaling
complexes failed to rescue B cell development in Fnip1/mice,
indicating that Fnip1 is required for B cell development down-
stream of the pre-BCR (and perhaps the BCR as well). Whereas
mice deficient in other signaling molecules including Src, Syk,
and Tec family PTKs, the adaptor protein SLP-65, and the
Ca2+ signaling molecules PLCg1/2 and the p85 subunit of PI3K
also exhibit impaired B cell development at the large pre-B cell
stage (see Herzog et al., 2009, for review), we find that these
pathways (as well as important transcriptional mediators) are
expressed or activated normally in Fnip1/ pre-B cells after
a-Igb crosslinking. A second unique feature of Fnip1 is that
loss of Fnip1 blocks pre-BCR-induced differentiation, whereas
pre-BCR-induced proliferation (synergistic with IL-7) and allelic
exclusion of the IgH chain loci remain intact. This is in contrast
to disruption of the membrane portion of IgH, Iga and Igb, or
Syk and Zap70, which result in blocked proliferation, differentia-
tion, and allelic exclusion (Kurosaki et al., 2010). A third unique
feature is that loss of Fnip1 potently inhibits transformation
and/or survival by Myc, whereas disruption of another pre-BCR
signaling molecule Igm (which also blocks B cell development at
the pre-B cell stage) results in significantly accelerated Myc-
induced transformation. These results collectively highlight that
Fnip1 functions in a distinct manner from most of the known
pre-BCR signaling molecules.
Fnip1 was cloned based on its interactions with Folliculin and
AMPK in kidney cells (Baba et al., 2006) and was subsequently
shown to interact with Fnip2. Here, we find that AMPK is acti-
vated normally in pre-B cells from Fnip1/ mice relative to WT
mice. In addition, we find increased expression of essential
AMPK-induced mitochondrial metabolic genes and increased
glucose uptake and mitochondrial biogenesis in Fnip1/ pre-
B cells. However, whereas AMPK activation in WT pre-B cellsshuts down mTOR-mediated anabolic (ATP and bioprecursor-
consuming) growth (Gwinn et al., 2008), AMPK fails to inhibit
mTOR-mediated growth in Fnip1/ pre-B cells, which corre-
lates with decreased energy balance (decreased ATP) and
increased sensitivity to apoptosis after pre-BCR activation,
nutrient or IL-7 deprivation, or oncogene activation. These
results, combined with previous studies by Baba et al. (2006)
in HEK cells, suggest that Fnip1 acts downstream of AMPK to
help maintain ‘‘metabolic homeostasis’’ in B lineage cells during
metabolic stress (see Figure S5D for model). Recent studies
indicate that disruption of AMPK-activator LKB also inhibits
pre-TCR-mediated T cell development (Tama´s et al., 2010),
and disruption of LKB1 in hematopoietic stem cells results in
dysregulated mTOR, increased cell growth, and decreased
survival of differentiated hematopoietic cells (Gan et al., 2010;
Gurumurthy et al., 2010; Nakada et al., 2010). Similar to Fnip1
deficiency, hematopoietic cell development is not rescued by
rapamycin alone, indicating that Fnip1 and LKB1 may function
in both mTORC1-dependent and -independent manners.
Indeed, B cell development in Fnip1/mice can only be partially
rescued by a combination of rapamycin (which inhibitsmTORC1)
and IL-7 (which stimulates glucose uptake and OXPHOS).
Whereas both Fnip1 and Fnip2 are expressed during B cell
development in WT mice, only Fnip2 is significantly regulated
with expression peaking in immature B cells. In addition, Fnip2
mRNA levels increase in Fnip1-null pre-B cells (data not shown).
These results suggest that Fnip1 and Fnip2may only be active as
heterodimers, which would explain why Fnip2 does not compen-
sate for the absence of Fnip1. Targeted disruption of the Fnip2
gene in mice should shed light on this issue.
An important distinction between Fnip1-null pre-B cells, which
exhibit increased mTOR activity, and other human diseases
whereby mTOR is dysregulated is the absence of benign or
malignant overgrowth. For example, mutations in LKB1, PTEN,
FLCN, and TSC1/2 result in deregulated mTOR and overgrowth
(hamartoma) syndromes or cancer in humans (see Shackelford
and Shaw, 2009, for review). In addition, loss-of-function muta-
tions in the PPKAG2 gene encoding the a subunit of AMPK result
in familial cardiac hypertrophy and Wolf-Parkinson’s-White
syndrome, overgrowth diseases characterized by cardiac hyper-
trophy and arrhythmias resulting from dysregulated mTOR (Arad
et al., 2007). We find that loss of Fnip1 also results in cardiac
hypertrophy and excessive growth of pre-B cells characterized
by dysregulated mTOR. However, we have not observed
transformation of any cell types including pre-B cells, and we
find that loss of Fnip1 inhibits pre-B cell lymphomagenesis by
the c-Myc oncogene, which potently drives transformation in
part by increasing the metabolic capacity of cancer cells (see
Dang et al., 2009, for review). Thus, our results suggest the
existence of a ‘‘metabolic checkpoint’’ during B cell develop-
ment, which inhibits the maturation and survival of pre-B cells
that are ‘‘metabolically insufficient,’’ either because of mutations
that disrupt energy- or bioprecursor-generating pathways and/
or because of excessive energy or bioprecursor consumption.
Inhibition of Fnip1 could provide a novel mechanism to limit
the fuel necessary to support cancer cell metabolism (Vander
Heiden et al., 2009), thus selectively sensitizing highly metabolic
cancer cells for apoptosis in response to chemotherapy or
metabolic stress.Immunity 36, 769–781, May 25, 2012 ª2012 Elsevier Inc. 779
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Mice
VDJ9HyHEL10 heavy chain knockin mice and HyHEL10 light chain transgenic
mice were provided by J. Cyster (Allen et al., 2007). Ighmtm1Cgn, TgN(IgHMyc)
22Bri, and Rag2/ mice and Rag2/Il2rg/ mice were purchased from
Jackson Laboratories and Taconic Farms, Inc. Fnip1/ mice were screened
and maintained by genomic PCR analysis after amplification with Fnip1
forward (50-ACTTGTCGCCATAGTTCTTCACTG-30) and reverse (50-CCAACT
TACCATCTAGGAAACACCC-30) oligonucleotides. Mice were housed under
specific-pathogen-free conditions. Mouse procedures were approved by the
Institutional Animal Care and Use Committees of Celltech R&D, Inc., and the
University of Washington.
Immunoblot Analysis
Immunoblot analyses were performed as previously described (Iritani et al.,
1997) with rabbit polyclonal antibodies specific for Fnip1 (anti-hFNIP1; Abcam,
MA); b-Actin, Syk, Btk (Santa Cruz Biotech); Blnk, P-Tyr96 Blnk, Akt, P-Ser473
Akt, P-Thr308 Akt, P-Ser176/180IKKa/b, P-Ser240/244 S6 Ribosomal Protein,
S6 Ribosomal Protein, P-Thr172AMPK, P-Erk, total Erk (Cell Signaling),
donkey a-goat IgG HRP (Santa Cruz), goat a-rabbit IgG HRP and goat
a-mouse IgG HRP (Bio-Rad Laboratories), and 4G10 antibody (Upstate
Biotech).
Flow Cytometry and Cell Sorting
BM, thymus, and spleen were stained with fluorescent-conjugated antibodies
specific for CD5, B220, CD21, CD25, CD22.2, CD62L, IAb, CD23, CD43, IgM,
IgMa, IgMb, l5, Igm, Igk, pS6R, BrdU, Annexin V, BP1, HSA, CD5, CD4, CD8,
and Lysozyme and analyzed by flow cytometry as previously described (Habib
et al., 2007). Mitochondrial staining was performedwithMitoTracker green dye
(Molecular Probes).
Cell Proliferation and Viability
BM cells were labeled with CFSE and then cultured in the presence or absence
of IL-7 (10 ng/ml) for 4 days. Cell division was determined by flow cytometry on
gated B220lo cells (Habib et al., 2007). BM cells were stained with a-B220,
a-CD43, and 7AAD (Invitrogen) or a-annexinV, and cell viability was analyzed
by flow cytometry.
Statistical Analysis
Data were analyzed with the Student’s one- or two-tailed t test. Kaplan-Meier
curve statistics were performed with Log-rank Mantel-Cox test. p < 0.05 were
considered as significant values.
ACCESSION NUMBERS
The microarray data are available in the Gene Expression Omnibus (GEO)
database (http://www.ncbi.nlm.nih.gov/gds) under the accession number
GSE37687.
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